PROVIDENCE — Immunolgy engineering biotech firm EpiVax Inc. has launched EpiVax Oncology Inc., a venture-backed spinoff focused on the development of personalized therapeutic cancer vaccines. EpiVax Oncology, an independent company, is conducting a $2 million bridge capital raise to prepare for an Investigational New Drug application as well as a $10 million to $25 million…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.